336.74
Overview
News
Price History
Option Chain
Financials
Why SYK Down?
Discussions
Forecast
Stock Split
Dividend History
Stryker Corp stock is traded at $336.74, with a volume of 2.05M.
It is up +1.97% in the last 24 hours and up +1.21% over the past month.
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
See More
Previous Close:
$330.25
Open:
$332.82
24h Volume:
2.05M
Relative Volume:
0.76
Market Cap:
$129.09B
Revenue:
$25.27B
Net Income/Loss:
$3.34B
P/E Ratio:
39.00
EPS:
8.6334
Net Cash Flow:
$4.57B
1W Performance:
+5.51%
1M Performance:
+1.21%
6M Performance:
-5.03%
1Y Performance:
-16.55%
Stryker Corp Stock (SYK) Company Profile
Name
Stryker Corp
Sector
Industry
Phone
(269) 385-2600
Address
1941 STRYKER WAY, PORTAGE, MI
Compare SYK vs ABT, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
SYK
Stryker Corp
|
336.74 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
ABT
Abbott Laboratories
|
104.49 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
MDT
Medtronic Plc
|
84.22 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
BSX
Boston Scientific Corp
|
45.51 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
83.04 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Stryker Corp Stock (SYK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Leerink Partners | Outperform |
| Feb-20-26 | Initiated | William Blair | Outperform |
| Jan-27-26 | Resumed | TD Cowen | Hold |
| Jan-06-26 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-19-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Sep-18-25 | Initiated | Rothschild & Co Redburn | Neutral |
| Feb-26-25 | Resumed | Citigroup | Buy |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-10-24 | Initiated | Wolfe Research | Outperform |
| May-30-24 | Initiated | Goldman | Neutral |
| May-22-24 | Upgrade | Needham | Hold → Buy |
| Jan-31-24 | Upgrade | Canaccord Genuity | Hold → Buy |
| Oct-20-23 | Initiated | ROTH MKM | Buy |
| Sep-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-25-23 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jan-09-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-28-22 | Upgrade | Edward Jones | Hold → Buy |
| Jul-21-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-13-22 | Initiated | Truist | Hold |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-15-22 | Resumed | Evercore ISI | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-10-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-07-21 | Initiated | Loop Capital | Buy |
| Sep-14-21 | Resumed | Raymond James | Mkt Perform |
| Jul-28-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jun-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| May-25-21 | Initiated | Barclays | Underweight |
| Oct-06-20 | Initiated | Northland Capital | Market Perform |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-20 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-01-20 | Downgrade | Goldman | Buy → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Buy |
| Jan-08-20 | Initiated | SunTrust | Hold |
| Jan-07-20 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-30-19 | Reiterated | BTIG Research | Buy |
| Nov-05-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-30-19 | Reiterated | BofA/Merrill | Buy |
| Jul-02-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-30-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Buy |
| Jan-02-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Aug-16-18 | Initiated | BTIG Research | Buy |
| Jun-27-18 | Initiated | Bernstein | Mkt Perform |
| Apr-27-18 | Reiterated | Stifel | Buy |
View All
Stryker Corp Stock (SYK) Latest News
Lyle Stein's Top Picks: ExxonMobil, iShares MSCI South Korea ETF & Stryker - BNN Bloomberg
Exploring Analyst Estimates for Stryker (SYK) Q2 Earnings, Beyond Revenue and EPS - Yahoo Finance
Stryker's Q2 Results Likely to Reflect Recovery of Q1 Deferred Orders - Yahoo Finance
Stryker Corp (SYK) Cash Flow - TradingKey
Stryker stock trades near highs as orthopedic demand supports revenue growth - Ad-hoc-news.de
Stryker Corp (SYK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Stryker Corp. stock outperforms competitors on strong trading day - MarketWatch
SYK|Stryker Corp|Price:330.250|Chg%:+11.440 - TradingKey
Stryker Corp Stock (SYK) Moved Up by 3.15% on Jul 24: Facts Behind the Movement - TradingKey
Stryker Gains as Recovery Optimism Builds Ahead of Q2 Results - Moomoo
Stryker Corp Stock (SYK) Closed Up by 3.21% on Jul 23: Drivers Behind the Movement - TradingKey
Stryker Corp (SYK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Stryker stock holds gains as medical device growth supports valuation - AD HOC NEWS
Stryker Corp (SYK) Shares Surge 3.1% -- What GF Score of 92 Tells Investors - GuruFocus
The Zacks Analyst Blog Highlights Qualcomm, Intuitive Surgical, Stryker, Frequency Electronics and Good Times Restaurants - Yahoo Finance
Stryker (SYK) Offers Attractive Valuations Amid Market Shifts - GuruFocus
Stryker stock trades steadily as medical device growth supports valuation - AD HOC NEWS
Boston Scientific Settles With Stryker In Spine Device IP Fight - Law360
Top Stock Reports for Qualcomm, Intuitive Surgical & Stryker - Yahoo Finance
Stryker Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Global Robotic Endoscopy Devices Market is Predicted to Exhibit Remarkable Growth at a CAGR of ~10% by 2034 | DelveInsight - GlobeNewswire Inc.
Boston Scientific, Stryker Settle Surgical Device Patent Dispute - Bloomberg Law News
Stryker Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Stryker stock trades steadily as recent earnings and growth investments shape outlook - Ad-hoc-news.de
Stryker stock builds on earnings momentum after 16 July 2026 update - Ad-hoc-news.de
Stryker stock trades on its latest reported growth - ad-hoc-news.de
Mako Handheld Robotic Knee System Launch Might Change The Case For Investing In Stryker (SYK) - Yahoo Finance
Is Stryker Corp (SYK) a Bargain After 3.4% Drop? GF Value Says U - GuruFocus
Stryker Corp. stock underperforms Friday when compared to competitors - MarketWatch
Stryker Corp Stock (SYK) Moved Down by 3.42% on Jul 17: A Full Analysis - TradingKey
Stryker stock trades near highs as robotics and trauma growth support valuation - ad-hoc-news.de
Stryker Launches Mako RPS to Expand Robotic Knee Surgery Portfolio - The Globe and Mail
Stryker Corp (XTER:SYK) Stock Price, Trades & News - GuruFocus
Stryker (SYK) Launches Mako RPS Handheld Robot for Knee Replacem - GuruFocus
Stryker Shares Rise After Commercial Launch of Mako Robotic Power System - Moomoo
Stryker (SYK) Introduces Mako RPS for Total Knee Replacements - GuruFocus
Stryker launches Mako RPS handheld robotic knee system in U.S. - Investing.com
Stryker expands Mako robotics portfolio with full market release of Mako RPS - Finviz
Stryker expands Mako robotics portfolio with full market release of Mako RPS – Company Announcement - Financial Times
Stryker's quarterly earnings preview: What you need to know - MSN
Stryker Corp (SYK) Stock Down 6.2% -- Now Undervalued? GF Score: 92/100 - GuruFocus
Goldman Sachs Adjusts Price Target on Stryker to $339 From $363, Maintains Neutral Rating - Moomoo
Stryker Corp Stock (SYK) Moved Down by 5.49% on Jul 14: A Full Analysis - TradingKey
Fund Update: 43,404 STRYKER (SYK) shares added to Douglas Lane & Associates, LLC portfolio - Quiver Quantitative
Stryker Slides As Investors Reassess Cyberattack Recovery Ahead Of Q2 Results - Quiver Quantitative
RBC Capital Maintains Stryker Corp(SYK.US) With Buy Rating, Maintains Target Price $435 - Moomoo
BTIG Research Adjusts Stryker Price Target to $371 From $379, Maintains Buy Rating - Moomoo
Piper Sandler reiterates Stryker stock rating on Mako strength - Investing.com
Piper Sandler reiterates Stryker stock rating on Mako strength By Investing.com - Investing.com Canada
Stryker Corp Stock Operating Data - GuruFocus
Stryker Corp (FRA:SYK0) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Stryker Corp Stock (SYK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):